Addendum
Sotatercept (pulmonary arterial hypertension) – Addendum to Project A24-96
Report documents
-
Addendum
Sotatercept (pulmonary arterial hypertension) – Addendum to Project A24-96
Dossier assessment
Indication:
Treatment of pulmonary arterial hypertension in adult patients with WHO Functional Class II to III, to improve exercise capacity
Result of dossier assessment:
unchanged after addendum: Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2025-03-06 A G-BA decision was published.
Project details
- Project no.
- A25-14
- Commission
- Commission awarded on 28.01.2025 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
- https://doi.org/10.60584/A25-14_en
Connected Projects
-
Dossier assessment
Sotatercept (pulmonary arterial hypertension) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed